Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

28.01USD
21 Sep 2017
Change (% chg)

$-0.26 (-0.92%)
Prev Close
$28.27
Open
$28.22
Day's High
$28.37
Day's Low
$27.95
Volume
1,575,905
Avg. Vol
3,967,225
52-wk High
$29.50
52-wk Low
$10.04

Latest Key Developments (Source: Significant Developments)

Exelixis Q2 earnings per share $0.06
Wednesday, 2 Aug 2017 04:05pm EDT 

Aug 2 (Reuters) - Exelixis Inc :Exelixis announces second quarter 2017 financial results and provides corporate update.Q2 revenue $99 million versus I/B/E/S view $85.3 million.Q2 earnings per share $0.06.Q2 earnings per share view $0.04 -- Thomson Reuters I/B/E/S.Exelixis Inc says company is reiterating its previously provided guidance that total costs and operating expenses for full year.  Full Article

Exelixis announces settlement of dispute with Genentech
Thursday, 20 Jul 2017 07:00am EDT 

July 20 (Reuters) - Exelixis Inc :Exelixis announces settlement of dispute with Genentech regarding companies’ collaboration agreement for Cobimetinib.Exelixis Inc - ‍Companies define new revenue and cost-sharing terms for all commercial applications of Cobimetinib​.Exelixis Inc - ‍Cobimetinib's clinical development program includes three ongoing or planned phase 3 pivotal trials​.Exelixis Inc - ‍Settlement of dispute with Genentech, member of Roche Group, on collaboration for development,commercialization of Cobimetinib.Exelixis Inc - ‍Exelixis remains eligible for royalties on Cotellic sales according to terms of original 2006 agreement​.  Full Article

Exelixis Q1 earnings per share $0.05
Monday, 1 May 2017 04:05pm EDT 

May 1 (Reuters) - Exelixis Inc ::Exelixis announces first quarter 2017 financial results and provides corporate update.Q1 earnings per share $0.05.Q1 revenue $80.9 million versus I/B/E/S view $65.2 million.Q1 earnings per share view $-0.01 -- Thomson Reuters I/B/E/S.Exelixis -reiterating previously provided guidance that total costs and operating expenses for full year will be between $290 million and $310 million for 2017.  Full Article

Exelixis' cabozantinib granted orphan drug designation
Monday, 6 Mar 2017 09:04am EST 

Exelixis Inc : Exelixis' cabozantinib granted orphan drug designation for the treatment of hepatocellular carcinoma .Exelixis inc - exelixis has guided that data from trial are expected in 2017.  Full Article

Exelixis announces clinical trial collaboration with Roche
Monday, 27 Feb 2017 06:59am EST 

Exelixis Inc : Exelixis announces clinical trial collaboration with Roche to evaluate cabozantinib and atezolizumab in locally advanced or metastatic solid tumors . Exelixis Inc - expect to begin patient enrollment mid-year 2017 .Exelixis - study will evaluate potential of this combination in multiple solid tumors, including advanced renal cell carcinoma, urothelial carcinoma.  Full Article

Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab
Friday, 17 Feb 2017 05:02pm EST 

Exelixis Inc : Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab in refractory metastatic urothelial carcinoma and other genitourinary tumors . Exelixis Inc - Recommended doses for ongoing expansion cohorts and future potential trials identified for doublet and triplet combinations .Exelixis - Data from Part II also demonstrate that using cabozantinib with two immunotherapy agents is well-tolerated with promising early activity.  Full Article

Genentech withdraws counterclaim against Exelixis in JAMS arbitration​
Monday, 9 Jan 2017 05:13am EST 

Exelixis Inc : Update on dispute between Exelixis and Genentech, a member of the Roche group . Exelixis relieved of $18.7 million of disputed costs . Genentech withdrew counterclaim against company in ongoing JAMS arbitration concerning "alleged breaches of parties' collaboration agreement" . Genentech's action does not address claims related to its clinical development, pricing and promotional costs for COTELLIC in United States .Genentech has not confirmed how it will allocate promotional costs with respect to collaboration's promotion of other combination therapies.  Full Article

BRIEF-Exelixis and Ipsen amend exclusive licensing agreement for commercialization,development of Cabozantinib to include Canada
Wednesday, 21 Dec 2016 01:18am EST 

Exelixis Inc : Press release - Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include canada . Exelixis - Amendment enhances productive year with Cabometyx regulatory approvals and commercial launches in United States and European Union . Says Exelixis to receive $10 million upfront payment, with subsequent regulatory and commercial milestones . Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of Cabozantinib to include Canada . Says Ipsen is currently initiating launch of Cabometyx in EU .Says regulatory filing in canada is expected in 2017, with regulatory approval anticipated in early 2018.  Full Article

Exelixis announces Q3 and YTD 2016 financial results
Thursday, 3 Nov 2016 04:07pm EDT 

Exelixis Inc : Exelixis announces third quarter and year to date 2016 financial results and provides corporate update . Q3 loss per share $0.04 . Q3 revenue $62.2 mln versus $9.9 mln . Q3 revenue view $45.5 mln -- Thomson Reuters I/B/E/S .Q3 earnings per share view -$0.12 -- Thomson Reuters I/B/E/S.  Full Article

Exelixis says entered privately negotiated exchange agreements with certain holders
Monday, 22 Aug 2016 08:54am EDT 

Exelixis Inc : Entered into privately negotiated exchange agreements with certain holders of 4.25 pct convertible senior subordinated notes due 2019 . Holders agreed to exchange an aggregate principal amount of approximately $71.3 million of notes held by them . Exchange for an aggregate of approximately 13.4 million shares of the company’s common stock Source: (http://bit.ly/2bbqXzk ) Further company coverage: [EXEL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Ipsen and Exelixis announce Phase 2 results of CABOSUN trial

* ANNOUNCED ON SUNDAY, RESULTS FROM PHASE 2 CABOSUN TRIAL OF CABOZANTINIB VERSUS SUNITINIB IN PREVIOUSLY UNTREATED ADVANCED RENAL CELL CARCINOMA